Grimberg A, et al. - In the present study, researchers compared racial/ethnic proportions of subjects receiving growth hormone (GH) treatment to the expected proportions as well as evaluated racial/ethnic differences in subject characteristics at GH treatment initiation. It was noted that white subjects exceeded the expected frequency (63%) for all indications (83%) and each separately, ranging from 73% for congenital GH deficiency (GHD) to 85% for idiopathic short stature. They found that black subjects with congenital GHD had lower stimulated GH peaks and started GH treatment at younger ages, while those with acquired GHD had lower birth weights. The results of this study revealed that overrepresentation of white children among those receiving GH treatment in the US Pfizer International Growth Study (KIGS) registry reflects racial/ethnic treatment biases, not just differences in growth rates.